Pharma's Almanac: Nice Insight's Content Community

Articles
Expert Interviews
Roundtable
Press Releases
Videos
Thought Leaders

Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing

SCYNEXIS

Sort By

Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us
Nice Insight
That's Nice

Reach Out Team

Contact Us
Advertise

My Account

Login/Sign up

Site

Privacy Policy
Terms And Conditions

© 2024 PHARMA’S ALMANAC. All rights reserved.

1 / 1

1 / 1

Q: What’s the key to being a leader in the industry?

Leadership

Q: What’s the key to being a leader in the industry?

Pharma's Almanac

PAO-03-022-RT-02March 11, 2022

Q: What important company milestone do you anticipate reaching in 2022?

Milestones

Q: What important company milestone do you anticipate reaching in 2022?

Pharma's Almanac

PAO-03-022-RT-01March 11, 2022

SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp

Toxicology

SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp

SCYNEXIS

PR-M06-19-NI-002June 04, 2019

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

Drug Development

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

SCYNEXIS, Inc.

PR-M07-18-NI-039July 12, 2018